An MIT economist argues that botched incentives, rather than scientific hurdles, are frustrating the quest for an HIV vaccine. The point that jumped out at us the most:
It has become increasingly apparent that an HIV vaccine may need to be administered in combination with antiretroviral drugs, even if a stand-alone vaccine remains the ultimate goal for some researchers. In that case, we will need to create stronger incentives for manufacturers of antiretroviral drugs to get into the business...
Published on November 10, 2009 08:45